This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Art Pappas
Managing Partner at Pappas Capital

Profile

Art has over 40 years of experience as a pharmaceutical industry executive and venture capital investor in life science companies. Art founded Pappas Capital in 1994, and over the past twenty-six years the firm has managed more than $540 million in capital and invested in more than 85 companies.

Art currently serves as a director for Aura Biosciences, OrphoMed and Reneo Pharmaceuticals, and as a board observer for Amplyx Pharmaceuticals and Real Endpoints. Prior to founding Pappas Capital, Art held senior leadership positions at Glaxo Holdings, Abbott International, Merrell Dow Pharmaceuticals and the Dow Chemical Company. He previously served as Chairman for CoLucid Pharmaceuticals, as a director for Afferent Pharmaceuticals, Arix Bioscience, Chimerix, Quintiles Transnational Corp., TYRX, Syntonix Pharmaceuticals, LEAD Therapeutics and Embrex; and as a board observer for Balance Therapeutics, Kezar Life Sciences, Milestone Pharmaceuticals and Plexxikon.

Art serves on the boards of the North Carolina Biotechnology Center, The Wistar Institute, the Duke Cancer Institute, and the Medical University of South Carolina. Art is a decorated Vietnam veteran, having served as an officer in the US Army 101st Airborne Division and with 2nd PSYOP Airborne JFK Special Warfare. Art received a BS in biology from The Ohio State University and an MBA in finance from Xavier University.

Agenda Sessions

  • ADVANCE LIVE SESSION - The year of the IPO and the coming of age of the SPACs

    12:00pm